Study #2023-0260
A phase 1b open-label multicenter study of OP-1250 in combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib, with the mTOR inhibitor Everolimus, or with CDK4 Inhibitor Atirmociclibin in adult subjects with advanced and/or metastatic HR positive, HR2 negative breast cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib
Description
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) in combination with everolimus. Treatment Group 4: Palazestrant (OP-1250) in combination with atirmociclib.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Study phase:
Phase I
Physician name:
Jason Mouabbi
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.